ARVINAS SELECTS CERTARA’S D360 TO ADVANCE SPEED AND EFFICIENCY OF DISCOVERY RESEARCH

In February 2020, we announced that Certara’s discovery research relationship with Arvinas had expanded to include a greater diversity of small molecule drug discovery projects and data sources. In 2017, Arvinas switched over to D360 from their former, legacy informatics reporting system. Their growing informatics needs were not being met by their legacy system. They wanted to easily view and manipulate data into tables, conduct SAR analysis, and have options for form and spreadsheet views, all within their informatics platform. After seeing D360’s capabilities, the Arvinas team knew that it would meet their current and ongoing needs, and they selected to move forward with D360 and recently expanded their use of D360.

Like most non-enterprise and agile biopharmaceutical companies, Arvinas does not have a large IT team and does not desire heavy IT infrastructure. To meet the ever growing demand of simplifying deployment and maintenance of solutions, D360 was implemented and hosted in the cloud. They have increased the number of data sources and complexity of data, which are now seamlessly integrated with D360 providing complete transparency to their end users. They currently have approximately 70 scientists using D360, running over 700 distinct D360 queries.

"We need to be able to query, pivot and dive deep into our drug discovery data, and D360 is the best platform we have found for that. Compared to our previous research informatics solution, D360 is saving us hundreds of hours annually on data analysis. That is an important contribution to our research. The Certara team is tenacious and resourceful. They always find a solution. That’s what has made our relationship so successful."

Dr. Keith Hornberger
Director of Chemistry
Arvinas
Arvinas is the pioneer and clinical-stage leader in the exciting, new area of targeted protein degradation. Its proprietary PROTAC® (proteolysis-targeting chimera) protein degraders are chimeric, modular small molecules, which harness the body’s natural protein disposal system, the ubiquitin-proteasome system, to induce the degradation of disease-causing proteins. Arvinas’ current drug discovery focus areas include metastatic prostate cancer, locally-advanced or metastatic breast cancer, and neurodegenerative diseases.